American College of Cardiology

AUGUST 7, 2024

In this week’s View, Dr. Eagle looks at post-capillary pulmonary hypertension in heart failure and the revised European guideline definition. He then explores obesity in adolescents and its impact on our societal health.

Obesity 61

Obesity Pulmonary Hypertension TAVR 61

American College of Cardiology

JUNE 28, 2024

For the treatment of pulmonary arterial hypertension (PAH), is sildenafil 80 mg TID noninferior to sildenafil 5 mg TID for all-cause mortality?

Pulmonary 58

Pulmonary Hypertension Article 58

American College of Cardiology

MARCH 11, 2025

Pulmonary hypertension (PH) is a rare condition that reportedly affects 1% of the global population, although estimates vary on the basis of age group and setting.

Pulmonary 56

Pulmonary Hypertension Cancer Article 56

American College of Cardiology

APRIL 4, 2024

What are the short-term outcomes for patients with native or surgically repaired right ventricular outflow tract (RVOT) undergoing transcatheter pulmonary valve replacement (TPVR) with a self-expanding valve?

Pulmonary 60

Pulmonary Outcomes Article 60

American College of Cardiology

APRIL 29, 2024

What is the real-world lesion durability of pulmonary vein isolation (PVI) with pulsed-field ablation (PFA) among patients with clinically indicated redo procedures?

Pulmonary 56

Pulmonary Ablation Article 56

American College of Cardiology

JANUARY 2, 2024

What are the contemporary management strategies and associated outcomes in patients with high-risk pulmonary embolism (PE)?

Embolism 56

Embolism Pulmonary Outcomes Article 56

Journal of the American Heart Association

MARCH 13, 2025

In the article byTakajoetal, Mortality Patterns in Pediatric Pulmonary Vein Stenosis: Insights Into Right Ventricular Systolic Pressure Associations, which published online on January 17, 2025 (J Am Heart Assoc.2025;2025;14:e037908. Journal of the American Heart Association, Ahead of Print. 2025;2025;14:e037908. DOI:10.1161/JAHA.124.035037)

Pediatrics 45

Pediatrics Stenosis Pulmonary Article 45

The British Journal of Cardiology

JANUARY 16, 2024

Pulmonary hypertension is a rare disease, associated with a significant deterioration in quality of life, usually not curable and with an ominous prognosis. We present the case of a patient diagnosed with precapillary component pulmonary hypertension, with the finding of an arteriovenous fistula at the peripheral level.

Pulmonary 52

Pulmonary Hypertension Quality of Life Article 52

American College of Cardiology

JUNE 12, 2024

In this week’s View, Dr. Eagle looks at excess apolipoprotein-B and cardiovascular risk, then examines a recent meta-analysis on treating pulmonary arterial hypertension. Finally, Dr. Eagle shares some thoughts on a SMART-C collaborative meta-analysis of sodium-glucose cotransporter-2 inhibitors and major adverse cardiovascular outcomes.

Pulmonary 58

Pulmonary Hypertension Outcomes Article 58

American College of Cardiology

JANUARY 23, 2024

The goal of the A DUE trial was to compare the safety and efficacy of macitentan/tadalafil combination therapy versus macitentan and tadalafil monotherapies in patients with pulmonary arterial hypertension (PAH).

Pulmonary 53

Pulmonary Hypertension Article 53

American College of Cardiology

FEBRUARY 11, 2025

What is the safety and utility of invasive implanted hemodynamic monitoring (IHM) using the CardioMEMS™ HF System in pediatric patients with heart failure (HF) and pulmonary hypertension (PH)?

Pediatrics 56

Pediatrics Heart Failure Pulmonary Hypertension 56

American College of Cardiology

FEBRUARY 1, 2025

Pulmonary embolism (PE) continues to challenge clinicians with its complex presentation and potential for rapid deterioration. As the third leading cause of cardiovascular mortality in the U.S.

Embolism 45

Embolism Pulmonary Article 45

American College of Cardiology

DECEMBER 14, 2023

What is the impact on prognosis of the 2022 ESC/ERS pulmonary hypertension (PH) guidelines on the new redefined hemodynamic threshold for the diagnosis of precapillary PH?

Pulmonary 50

Pulmonary Hypertension Outcomes Article 50

ADN Center of Excellence

NOVEMBER 7, 2024

In this article, we’ll explore some of the leading fellowship specialties, what they entail, and the career paths they open for doctors committed to continuous learning and professional growth. Pulmonology A fellowship in pulmonology focuses on respiratory health, a field that has grown in importance in recent years.

Cancer 59

Cancer Academic Research Interventional Cardiology 59

American College of Cardiology

JUNE 28, 2024

™s Cordellaâ„¢ Pulmonary Artery Sensor System for the treatment of patients with NYHA class III heart failure (HF). Food and Drug Administration (FDA) on June 24 gave premarket approval for Endotronix, Inc.’s

Pulmonary 45

Pulmonary Heart Failure Article 45

American College of Cardiology

FEBRUARY 25, 2025

William Boden and Bradley Maron discuss the latest advancements in managing pulmonary hypertension caused by left heart disease. In this interview, Drs.

Heart Disease 50

Heart Disease Pulmonary Hypertension Article 50

American College of Cardiology

MAY 1, 2024

In this week’s View, Dr. Eagle looks at the durability of pulmonary vein isolation using pulsed-field ablation, then examines genetic penetrance of dilated cardiomyopathy in genotype-positive relatives.

Cardiomyopathy 56

Cardiomyopathy Pulmonary Ablation TAVR 56

American College of Cardiology

APRIL 8, 2025

In this interview, Drs. Shashank Sinha and Anjali Vaidya discuss how to approach the treatment decision for CTEPH once a diagnosis has been made.

Pulmonary 64

Pulmonary Hypertension Article 64

Circulation

JANUARY 26, 2025

Circulation, Volume 151, Issue 4 , Page e32-e32, January 28, 2025.

Article 49

Article Pulmonary Circulation Hypertension 49

Circulation

NOVEMBER 24, 2024

Circulation, Volume 150, Issue 22 , Page e467-e467, November 26, 2024.

Article 45

Article Pulmonary Hypertension Circulation 45

Frontiers in Cardiovascular Medicine

MAY 8, 2024

Pulmonary arterial hypertension (PAH) is a chronic and progressive disease that eventually leads to heart failure (HF) and subsequent fatality if left untreated. Right ventricular (RV) function has proven prognostic values in patients with a variety of heart diseases including PAH.

Pulmonary 40

Pulmonary Hypertension Heart Disease Article 40

Circulation

MARCH 9, 2025

Circulation, Volume 151, Issue 10 , Page e686-e686, March 11, 2025.

Preserved Ejection Fraction 45

Preserved Ejection Fraction Article Heart Failure Pulmonary 45

American College of Cardiology

SEPTEMBER 2, 2024

The goal of the SHAM-PVI trial was to compare the clinical efficacy of cryoballoon pulmonary vein isolation (PVI) to a sham procedure in the treatment of symptomatic atrial fibrillation (AF).

Atrial Fibrillation 40

Atrial Fibrillation Pulmonary Article 40

Circulation

JANUARY 26, 2025

Circulation, Volume 151, Issue 4 , Page e31-e31, January 28, 2025.

Article 45

Article Pulmonary Hypertension Circulation 45

Journal of Cardiovascular Pharmacology

JULY 1, 2024

However, whether AMOTL2 is linked to pulmonary arterial hypertension (PAH) has not been addressed. Overexpression of AMOTL2 also led to a noteworthy decrease in vascular wall thickness, pulmonary artery area, and collagen deposition in rats with PAH. This work aimed to investigate the potential role of AMOTL2 in PAH.

Pulmonary 40

Pulmonary Hypertension Physiology Article 40

International Journal of Cardiovascular Sciences

SEPTEMBER 21, 2023

Access below the articles from the thematic collection on Cardiometablism.

COVID-19 52

COVID-19 Article Obesity Cardiovascular Disease 52

American College of Cardiology

MAY 3, 2024

Acute pulmonary embolism (PE) is a frequently encountered diagnosis in both the emergency department (ED) and among hospitalized patients, with increasing incidence throughout the U.S.

Embolism 40

Embolism Pulmonary Outpatient Hospital 40

American College of Cardiology

SEPTEMBER 2, 2024

Compared with a sham procedure, pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation (AFib) burden at six months, according to results from the SHAM-PVI trial presented at ESC Congress 2024 in London and simultaneously published in JAMA.

AFIB 40

AFIB Pulmonary Quality of Life Atrial Fibrillation 40

American College of Cardiology

OCTOBER 29, 2024

The goal of the trial was to compare the efficacy and safety of large-bore mechanical thrombectomy (LBMT) with catheter-directed thrombolysis (CDT) in the treatment of intermediate-high risk pulmonary embolism (PE).

Thrombolysis 40

Thrombolysis Embolism Pulmonary Article 40

Journal of Cardiovascular Pharmacology

MARCH 13, 2024

Pulmonary arterial hypertension (PAH) is characterized by increased pulmonary vascular resistance, imposing overload on the right ventricle (RV) and imbalance of redox state. PAH induction was implemented by a single dose of MCT (60 mg/kg i.p.). Treatment with SFN (2.5 mg/kg/day i.p.)

Pulmonary 40

Pulmonary Hypertension Tricuspid Cardiac Function 40

American College of Cardiology

FEBRUARY 1, 2025

Pulmonary embolism (PE) mortality has increased over the past decade and racial and geographic disparities persist. Black women and men have an approximately two-fold higher age-adjusted mortality rate compared with White women and men, respectively.

Embolism 40

Embolism Pulmonary Article 40

European Journal of Heart Failure

DECEMBER 19, 2024

Initial macitentan and tadalafil combination therapy in pulmonary arterial hypertension (PAH) patients with or without cardiac comorbidities. 6MWD, 6-min walk distance; NT-proBNP, N-terminal pro-brain natriuretic peptide; PVR, pulmonary vascular resistance; WHO FC, World Health Organization functional class.

Pulmonary 40

Pulmonary Hypertension Research Article 40

Journal of Cardiovascular Electrophysiology

NOVEMBER 5, 2023

Abstract Introduction Carina breakthrough (CB) at the right pulmonary vein (RPV) can occur after circumferential pulmonary vein isolation (PVI) due to epicardial bridging or transient tissue edema. High-power short-duration (HPSD) ablation may increase the incidence of RPV CB.

Pulmonary 40

Pulmonary Ablation Atrial Fibrillation Article 40

Medical Xpress - Cardiology

DECEMBER 4, 2024

The perspectives and priorities of people living with chronic obstructive pulmonary disease (COPD) should be integrated into the development process of new therapies for COPD, according to a new commentary. The article is published in the Annals of the American Thoracic Society.

Article 40

Article Pulmonary 40

Journal of Cardiovascular Pharmacology

OCTOBER 30, 2023

Abstract: Pulmonary artery hypertension (PAH) is characterized by pulmonary arterial endothelial cells (PAECs) dysfunction and pulmonary artery smooth muscle cells (PASMCs) activation. For decades, the therapies for PAH based on stem cells have been shown to be effective.

Pulmonary 40

Pulmonary Hypertension Article 40

Journal of Cardiothoracic Surgery

FEBRUARY 8, 2024

The decision of whether to perform a large anatomic resection for a lung mass that is not definitely malignant comes often forward in the everyday practice of the thoracic surgeon. The general characteristics.

Article 40

Article Cancer Pulmonary 40

American College of Cardiology

MARCH 29, 2025

Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer and proximal deep-vein thrombosis or pulmonary embolism, based on findings from the API-CAT trial presented at ACC.25

Cancer 71

Cancer Thrombosis Embolism Pulmonary 71